Among others, the present invention provides a method for treating a neuropathic ocular pain disorder in a subject in need thereof, comprising: topically applying a therapeutically effective amount of a 1-di-isopropyl-phosphinoyl-alkane (DIPA) compound onto an ocular surface of the subject for at least one week, wherein the DIPA compound is dissolved in a liquid vehicle which is adapted for focused delivery of the DIPA compound to the ocular surface.

The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, and Z.sup. have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).

##STR00001##

The invention relates to compounds which correspond to the general formula (I) below:

##STR00001##

in which: R.sup.1 and R.sup.2 represent, independently of one another, a C.sub.4 to C.sub.12 acyclic hydrocarbon group; R.sup.3 represents H; a C.sub.1 to C.sub.12 acyclic hydrocarbon group with optionally one or more heteroatoms; a C.sub.5 or C.sub.6 cyclic hydrocarbon group; or a 5- or 6-membered heterocyclic group; R.sup.4 represents H or a C.sub.1 to C.sub.12 acyclic hydrocarbon group with optionally one or more heteroatoms; R.sup.5 and R.sup.6 represent, independently of one another, H; a C.sub.1 to C.sub.12 acyclic hydrocarbon group with optionally one or more heteroatoms; a C.sub.5 or C.sub.6 cyclic hydrocarbon group; or a 5- or 6-membered heterocyclic group; on the condition however that R.sup.5 and R.sup.6 do not each represent H.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as DIPA compounds, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in a solution, gel, lotion, cream, or ointment. The method of application may be with the surface of the finger, or via an applicator. The decrease is sebum secretion in certain subjects may result in skin conditions that enhance cosmetic appearance and ameliorate skin disorders.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as DIPA compounds, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

Embodiments of the present disclosure relate generally to novel achiral and chiral sulfur-, nitrogen- and phosphorus-containing ligands, designated as NNS-type, P(O)NS-type, PNS-type, SNNS-type, SNNP(O)-type, or SNNP-type polydentate ligands and transition metal complexes of these ligands, including iridium complexes having PNS-type and NNS-type ligands. The catalysts derived from these ligands and transition metal complexes may be used in a wide range of catalytic reactions, including hydrogenation and transfer hydrogenation of unsaturated organic compounds, dehydrogenation of alcohols and boranes, various dehydrogenative couplings, chemoselective hydrogenation of ,-unsaturated alcohols, and other catalytic transformations.

Provided is a method for purifying a phosphorus-containing olefin compound salt as a raw material or an intermediate that is useful to increase the purity of a target product in a method for producing an olefin compound and that can be applied to the production method, and a method for producing an olefin compound using a purified product obtained thereby. Specifically, provided is a method for purifying a phosphorus-containing olefin compound salt, comprising reprecipitating and/or recrystallizing a solid comprising at least one phosphorus-containing olefin compound salt selected from the group consisting of: a phosphorus-containing olefin compound salt A represented by the following formula (1): ##STR00001## wherein X.sub.1 and X.sub.2 are each independently F, Cl, Br, I, or H; W.sup.+s are the same or different and each is a monovalent cation comprising PR.sub.3 or P(OR).sub.3, provided that Rs are groups having a saturated or unsaturated structure containing C and H, are optionally bonded together to form a ring, and optionally contain an atom other than C and H; three Rs included in R.sub.3 and (OR).sub.3 are optionally the same or different; and M.sup. is a monovalent anion comprising an atom or a compound; and a phosphorus-containing olefin compound salt B represented by the following formula (2): ##STR00002## wherein X.sub.1, X.sub.2, W.sup.+, and M.sup. are as defined above, and Y is F, Cl, Br, I, H, an alkyl group, an alkyl ether group, a fluoroalkyl group, or a fluoroalkyl ether group; in a solvent, thereby obtaining a purified product of the phosphorus-containing olefin compound salt.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): ##STR00001##
or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M.sup.1, M.sup.2, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

A surface modified lithium titanate and preparation method thereof is provided. In the surface modified lithium titanate, the deactivating groups distributed on the surface of the lithium titanate are OPRRR, OP(OR)RR, OP(OR)(OR)R, and OP(OR)(OR)(OR), where R, R and R are identical or different C1C8 alkyl or alkenyl groups. The deactivating groups are bonded to the lithium titanate via a bond or a bridge. The exemplary surface modified lithium titanate can effectively lower its catalytic activity, reduce the gassing of lithium ion batteries, and therefore improve the high temperature storage and high temperature cycle performance of lithium titanate batteries. The exemplary preparation method is simple, has great repeatability, a low cost, low pollution to the environment, and is suitable for industrial production.